Possible Enzymatic Downregulation of the Natriuretic Peptide System in Patients with Reduced Systolic Function and Heart Failure: A Pilot Study
Table 4
Medication usage.
Laboratory Test
Normal Systolic Function
Reduced Systolic Function (Systolic Dysfunction)
Control
No Heart Failure
Heart Failure
ASA (N, (%))
14 (88)
11 (69)
13 (81)
Beta Blocker (N, (%))
10 (63)
15 (94)
11 (69)
ACE-inhibitor (N, (%))
8 (50)
11 (69)
11 (69)
Angiotensin Receptor Blocker (N, (%))
1 (6)
3 (19)
2 (13)
Spironolactone (N, (%))
2 (13)
9 (56)‡‡
8 (50)§
Diuretic (N, (%))
6 (38)§§
9 (56)
14 (88)§
Coumadin (N, (%))
1 (6)
3 (19)
4 (25)
Nitrates (N, (%))
6 (38)
3 (19)
3 (19)
Statin (N, (%))
14 (88)†
14 (88)†
9 (56)
Digoxin (N, (%))
0 (0)
5 (31)‡
4 (25)
Antiarrhythmic (N, (%))
0 (0)
2 (13)
3 (19)
p<0.05; §rEF + HF versus control, †rEF + HF versus rEF, and ‡ rEF versus control. §§p<0.01; rEF + dHF versus control and ‡‡ rEF versus control. Data represent means ± SD unless otherwise indicated.
